# A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation

> **NCT02823470** · PHASE4 · TERMINATED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 24 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** LUM/IVA
- **DEVICE:** activated smart device
- **DEVICE:** de-activated smart device

## Key facts

- **NCT ID:** NCT02823470
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-06
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Study terminated early due to slow recruitment of patients.
- **Last updated:** 2018-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02823470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02823470, "A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02823470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*